SouthState’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$840 Hold
14
– – ﹤0.01% 1174
2026
Q2
$802 Sell
14
-15
-52% -$822 ﹤0.01% 1151
2026
Q1
$1.64K Buy
29
+19
+190% +$1.11K ﹤0.01% 940
2025
Q4
$595 Sell
10
-29
-74% -$1.58K ﹤0.01% 1208
2025
Q3
$2.11K Sell
39
-15
-28% -$858 ﹤0.01% 926
2025
Q2
$2.97K Sell
54
-52
-49% -$3.06K ﹤0.01% 1016
2025
Q1
$7.49K Buy
+106
New +$7.13K ﹤0.01% 896

Other funds holding BMRN

SouthState's BMRN Position: Q3 2026 in Review

SouthState held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 14 shares worth $840. The position accounts for ﹤0.01% of the portfolio, ranked #1174.

SouthState first reported a position in BMRN in Q1 2025 and has held it in 7 quarters since. The position peaked at $7.49K in Q1 2025. 434 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • SouthState held 14 shares of BioMarin Pharmaceuticals worth $840 as of Q3 2026.
  • SouthState left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of SouthState's portfolio in Q3 2026, its #1174 holding.
  • SouthState first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
  • SouthState's BioMarin Pharmaceuticals position peaked at $7.49K in Q1 2025.
  • 434 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on SouthState's 13F filing for Q3 2026, filed 9 Nov 2026.